CBT‑I in Cancer Survivors: Small Subjective Gains, Unclear Objective Benefits — What the 2025 Cochrane Review Tells Clinicians
Posted innews Oncology Psychiatry

CBT‑I in Cancer Survivors: Small Subjective Gains, Unclear Objective Benefits — What the 2025 Cochrane Review Tells Clinicians

A 2025 Cochrane review of 21 RCTs (2431 participants) finds cognitive behavioural therapy for insomnia (CBT‑I) yields modest improvements in self‑reported insomnia and sleep quality in people with cancer versus inactive controls or aerobic activity; objective sleep changes and long‑term effects remain uncertain.
Calcium Supplementation During Pregnancy for Preventing Hypertensive Disorders: Current Evidence and Clinical Implications
Posted inClinical Updates Family Medicine & Nutrition news OB/GYN & Women's Health

Calcium Supplementation During Pregnancy for Preventing Hypertensive Disorders: Current Evidence and Clinical Implications

This review synthesizes recent randomized controlled trials and meta-analyses on calcium supplementation during pregnancy, evaluating its effectiveness in preventing hypertensive disorders such as pre-eclampsia and related maternal and neonatal outcomes.
Acupuncture for Cancer-Related Insomnia: Limited, Low-Certainty Benefits Compared with Sham or No Treatment; Inferior to CBT‑I
Posted inNeurology news Oncology

Acupuncture for Cancer-Related Insomnia: Limited, Low-Certainty Benefits Compared with Sham or No Treatment; Inferior to CBT‑I

A 2025 Cochrane review (5 RCTs, 402 patients, mainly women with breast cancer) finds very low- to moderate-certainty evidence that acupuncture delivers small, uncertain sleep diary benefits versus sham or inactive controls and is probably less effective than CBT‑I for insomnia in people with cancer.
FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations
Posted innews Oncology Urology

FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations

The FDA approved once‑daily niraparib plus abiraterone acetate and prednisone for adults with deleterious or suspected deleterious BRCA2‑mutated metastatic castration‑sensitive prostate cancer (CSPC), based on rPFS and interim overall survival benefits in the AMPLITUDE trial.
Medical and Surgical Treatments for Neurotrophic Keratopathy: What Randomized Trials Tell Us (and What They Don’t)
Posted innews Ophthalmology

Medical and Surgical Treatments for Neurotrophic Keratopathy: What Randomized Trials Tell Us (and What They Don’t)

A Cochrane review of seven RCTs (494 participants) finds low- to very low-certainty evidence that select medical therapies — notably recombinant human nerve growth factor — may improve corneal re-epithelialization in neurotrophic keratopathy; evidence on vision, sensitivity, and surgical options remains inconclusive.
Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know
Posted inNephrology news

Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know

A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and quality-of-life differences are uncertain, highlighting the need for individualized decisions and higher-quality research.